Aveo Pharmaceuticals, a Cambridge, MA-based developer of cancer drugs, has set a price range of $13 to $15 per share for its proposed initial public offering, according to an SEC filing. The firm says it expects to offer 7 million shares in the IPO, in addition to up to 1.05 million shares that would be sold to cover over-allotments. At $15 a share, the public debut could bring in a total of $120.75 million, according to the company. The company—which estimated it would raise $86.3 million in the IPO when it first revealed its plans to go public in December 2009—plans to list its stock on the NASDAQ stock market under the symbol “AVEO.”
By posting a comment, you agree to our terms and conditions.